



March 27, 2023

RE: Banzel[®], Combigan[®], Tazorac[®] Gel, and Welchol[®] Packets for Oral Suspension Coverage Changes Effective April 10, 2023

The following changes will take effect April 10, 2023. Complete prior authorization (PA) criteria can be found on the OHCA website at www.oklahoma.gov/ohca/pa. Pharmacy prior authorization forms can be found on the OHCA website at <https://oklahoma.gov/ohca/rxforms>.

Banzel[®]

Banzel[®] (rufinamide) will be brand preferred. Members currently utilizing generic rufinamide and who have a seizure diagnosis will be approved for continuation of therapy. Banzel[®] will continue to require PA for both the brand and generic formulations; the specific PA requirements for the anticonvulsants can be found in the “Central Nervous System/Behavioral Health” therapeutic category.

Combigan[®]

Combigan[®] (brimonidine/timolol 0.2%/0.5%) will be brand preferred. Brand Combigan[®] is a Tier-1 medication available without PA. Members currently utilizing generic brimonidine/timolol will need to switch to brand Combigan[®].

Tazorac[®] Gel

Tazorac[®] (tazarotene) 0.05% gel and 0.1% gel will require PA for all members. The specific PA requirements for Tazorac[®] can be found in the “Topical” therapeutic category. A PA request will need to be submitted for members currently utilizing tazarotene 0.05% gel or 0.1% gel with a patient-specific, clinically significant reason why the member cannot use tazarotene 0.1% cream, which is available without PA for members 20 years of age and younger.

Welchol[®] (Colesevelam) Packets for Oral Suspension

Welchol[®] packets for oral suspension will require PA. The specific PA requirements for the antihyperlipidemics can be found in the “Cardiovascular” therapeutic category. A PA request will need to be submitted for members currently utilizing Welchol[®] packets for oral suspension with a patient-specific, clinically significant reason why the member cannot use the oral tablet formulation of colesevelam, which is available without PA.

Reminder: Medications for Weight Loss

As authorized by OAC 315:30-5-72.1, medications for weight loss are currently not covered by SoonerCare.

Thank you for the services you provide to Oklahomans insured by SoonerCare!

SOONERCARE PHARMACY SERVICES • PHARMACY MANAGEMENT CONSULTANTS



ADDRESS

4345 N. Lincoln Blvd.
Oklahoma City, OK 73105



WEBSITES

oklahoma.gov/ohca
mysoonerCare.org



PHONE

Admin: 405-522-7300
Helpline: 800-987-7767